Drugs.com Blog

The Official Drugs.com Blog

New Drugs.com Compare Tool

March 28, 2018 By Drugs com

New Drugs.com Compare Tool

We are proud to announce the first release of the Drugs.com Medication Compare Tool (beta). Our team of developers have been very busy working on this tool and there are plenty of upgrades planned in the near future. See how your medications stack up against each other. View side-by-side comparisons of medication uses, ratings, reviews, […]

Filed Under: Business, Media, Patient Safety, Site Upgrades, Statistics

Q4 2013 Drug Sales Data Released: Tecfidera Growth On a Rapid Transit

February 10, 2014 By Drugs.com

Drugs.com has released the latest U.S. drug sales data. While the ranking of the top three drugs by sales — Abilify, Nexium and Humira — remains the same, Lilly’s Cymbalta drops from fourth to seventh and forfeits close to $319 million in sales due to generic availability. Nexium’s growth tapers too, possibly due to looming […]

Filed Under: Statistics

Q3 2013 Drug Sales Data Released: Top Five Drugs Each Post Over $1 Billion in Sales

November 7, 2013 By Drugs.com

The latest U.S. drug sales data has been released by Drugs.com. Rankings for the top five drugs by sales remain unchanged in the third quarter. Otsuka’s antipsychotic Abilify and AstraZeneca’s Nexium retain their number one and two spots, respectively. Nexium, the top proton pump inhibitor faces sizable over-the-counter competition, a looming Rx-to-OTC switch, and patent […]

Filed Under: Business, Statistics

Q2 2013 Drug Sales Data Released: Humira Climbs and Posts Double-Digit Growth

August 8, 2013 By Drugs.com

The latest U.S. drug sales data has been released by Drugs.com. Since Q2 2012, Otuska’s antipsychotic Abilify and AstraZeneca’s acid reducer Nexium have held either the number one or two spot in top dollar sales. This quarter, both agents continue to maintain their stronghold; each post close to $1.5 billion in sales. Humira, AbbVie’s key […]

Filed Under: Business, Media, Statistics

Q1 2013 Drug Sales Data Released: Rough U.S Flu Season Boosts Numbers for Tamiflu

May 5, 2013 By Drugs.com

The latest U.S. drug sales data has been released by Drugs.com. The top five drugs have minor shifts in rank but exhibit positive growth for Q1 2013. Abilify, Otsuka’s second generation antipsychotic, and Nexium, AstraZeneca’s leading acid blocker, rank as the top two drugs by sales for the fourth quarter in a row. Both agents […]

Filed Under: Media, Statistics

Q4 2012 Drug Sales Data Released: Abilify Overtakes Nexium as the Top Drug by Sales

February 7, 2013 By Drugs.com

The latest U.S. drug sales data have been released by Drugs.com. At the close of 2012, Otsuka’s antipsychotic Abilify overtakes AstraZeneca’s acid reducer Nexium and moves into the number one spot with over $1.47 billion in quarterly sales. Sales expanded for all five front-runners over the quarter, although none reached double-digit growth. There are no […]

Filed Under: Business, Statistics

Q3 2012 Drug Sales Data Released: Nexium and Abilify Remain the Leading Brands

November 21, 2012 By Drugs.com

The latest U.S. drug sales data has been released by Drugs.com. As in the previous quarter, proton-pump inhibitors, antipsychotics and statins remain in the top-selling therapeutic categories. Merck’s asthma and allergy preventive Singulair predictably drops out of the top five drugs due to Q3 patent loss. AstraZeneca’s Nexium, not forecast to lose patent protection until May 2014, […]

Filed Under: Statistics

Q2 2012 Drug Sales Data Released: Loss of Patent Protection Has Significant Effect

August 22, 2012 By Drugs.com

The latest U.S. drug sales data has been released by Drugs.com. Proton-pump inhibitors, antipsychotics, asthma therapeutics and statins remain the top selling categories. Plavix and Seroquel dipped in the second quarter due to loss of patent protection. Other top brands such as Singulair, Actos and Diovan are also due to be impacted by year’s end. […]

Filed Under: Business, Media, Statistics

New Drugs.com Stats Center Shows Top 100 U.S. Drug Sales Data

July 18, 2012 By Drugs.com

We are pleased to announce our new interactive stats center featuring quarterly sales data for the top 100 prescribed medicines by U.S. National Sales. Users can view charts showing the sales and unit data for the top 5 drugs plus granular data for the top 100, with graphs and links to other useful resources. This […]

Filed Under: Business, Statistics

A Side Effect of Michael Jackson’s Tragic Death – Consumer Health Education

June 29, 2009 By Drugs.com

A Side Effect of Michael Jackson’s Tragic Death – Consumer Health Education

Drugs.com reported a massive 20,900% increase (yes, you read that correctly – twenty thousand, nine hundred percent) in interest for information on the prescription medication Demerol – allegedly prescribed for the legendary entertainer Michael Jackson. More than 135,000 page views were logged on the Drugs.com web site by people researching Demerol this past Friday – […]

Filed Under: Statistics

Recent Posts

  • Saturday, April 28, 2018 is National Prescription Drug Take-Back Day April 23, 2018
  • New Drugs.com Compare Tool March 28, 2018
  • Drugs.com Receives eHealthcare Leadership Silver Award October 29, 2017
  • Drugs.com Recognized as ‘Health Information Website Brand of the Year’ in 2017 Harris Poll EquiTrend® Study May 9, 2017
  • REMS@FDA: An Upgraded Patient Safety Program July 26, 2016

Categories

  • Business
  • Commentary
  • Media
  • Mobile
  • Patient Safety
  • Site Upgrades
  • Statistics
  • Uncategorized

Copyright © 2018 Drugs.com - Return to Drugs.com